Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 51 to 75 of 361

Guidance and quality standards awaiting development
Title	Type
Botulinum toxin type A for preventing episodic migraine [ID6450]	Technology appraisal guidance
Brensocatib for treating moderate to severe non-cystic fibrosis bronchiectasis in people 12 years and over [ID6448]	Technology appraisal guidance
Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma [ID6437]	Technology appraisal guidance
Budesonide (Jorveza) for maintaining remission of eosinophilic oesophagitis in people 2 years and over [ID6486]	Technology appraisal guidance
Bupivacaine–meloxicam for treating postoperative pain [ID2728]	Technology appraisal guidance
Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731]	Technology appraisal guidance
Cabozantinib with atezolizumab for treating hormone-relapsed metastatic prostate cancer after 1 hormonal treatment [ID6387]	Technology appraisal guidance
CAEL-101 with standard care for untreated amyloid light chain amyloidosis [ID6210]	Technology appraisal guidance
Camizestrant as an add-on to palbociclib and abemaciclib for untreated hormone receptor-positive HER2-negative metastatic breast cancer with an ESR1 mutation [ID6535]	Technology appraisal guidance
Camizestrant with palbociclib for untreated oestrogen receptor-positive HER2-negative metastatic breast cancer after adjuvant endocrine treatment [ID6534]	Technology appraisal guidance
Camlipixant for treating refractory or unexplained chronic cough [TSID12072]	Technology appraisal guidance
Canagliflozin for treating type 2 diabetes in people 10 to 17 years [TSID11888]	Technology appraisal guidance
Capivasertib with abiraterone for treating hormone-sensitive metastatic prostate cancer with PTEN deficiency [ID6466]	Technology appraisal guidance
Capsule sponge tech for oesophageal cancer	Health technology evaluation
Carfilzomib in combination for untreated multiple myeloma when an autologous stem cell transplant is suitable [TSID12176]	Technology appraisal guidance
Catumaxomab for intraperitoneal treatment of malignant ascites in epithelial cellular adhesion molecule-positive cancers when further systemic anticancer treatment is unsuitable [ID12201]	Technology appraisal guidance
Cenobamate for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [TSID10214]	Technology appraisal guidance
Children and young people with disabilities and severe complex needs: integrated health and social care support	Quality standard
Clascoterone for treating acne vulgaris in people 12 years and over [TSID12136]	Technology appraisal guidance
Concizumab for preventing bleeding episodes in haemophilia A or haemophilia B [ID5099]	Technology appraisal guidance
Dabigatran etexilate for the secondary prevention of stroke after an embolic stroke of undetermined source [ID1417]	Technology appraisal guidance
Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma in people aged 12 to 17 [TSID11839]	Technology appraisal guidance
Dabrafenib, trametinib or both for treating BRAF V600 mutation-positive unresectable or metastatic melanoma in people aged 12 and over [TSID11838]	Technology appraisal guidance
Daratumumab for treating high-risk smouldering multiple myeloma [ID6214]	Technology appraisal guidance
Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435]	Technology appraisal guidance

Results per page

10
25
50
All